NEFOLO LTD

Executive Summary

NEFOLO LTD presents a low-risk profile based on available micro-entity financials, showing positive net assets and current assets sufficient to meet short-term liabilities. While liquidity has decreased over time, the company remains compliant with filings and under stable director control. Further review of asset composition and cash flow is advised for comprehensive risk assessment.

NEFOLO LTD - Analysis Report

Company Number: 13481798

Analysis Date: 2025-07-29 19:15 UTC

1. Risk Rating: LOW
   The company shows consistent positive net assets and net current assets in the latest accounts, with no overdue filings or signs of financial distress. The micro-entity status with modest asset levels and two employees suggests a small but stable operation.

2. Key Concerns:

• Significant reduction in current assets from £12,030 in 2021 to £630 in 2024, which may indicate reduced liquidity or operational scale.
• Fixed assets increased modestly to £713 in 2024 after being zero previously; the nature and necessity of these assets should be clarified.
• Share capital remains nominal at £10, which may limit capital buffer against liabilities or losses.

3. Positive Indicators:

• Net current assets improved to £1,163 in 2024, indicating positive short-term liquidity.
• No overdue accounts or confirmation statements, demonstrating regulatory compliance and good governance.
• Stable management with two directors having clear control and no disqualifications noted.

4. Due Diligence Notes:

• Investigate the reasons behind the steep decline in current assets from 2021 to 2024 and whether this impacts operational cash flow.
• Clarify the nature and valuation basis of fixed assets recorded in 2024.
• Review any off-balance sheet liabilities or contingent risks not visible in micro-entity accounts.
• Assess the revenue and profitability trends to verify sustainable operations beyond balance sheet snapshots.
• Confirm absence of any director conduct issues or legal actions given the small management team.